| Quarter | Score |
|---|---|
| 2022-Q1 | 55.2 |
| 2022-Q3 | 67.5 |
| 2022-Q4 | 50.3 |
| 2023-Q1 | 55.0 |
| 2023-Q2 | 65.3 |
| 2023-Q3 | 48.1 |
| 2023-Q4 | 43.5 |
| 2024-Q1 | 49.3 |
| 2024-Q2 | 43.9 |
| 2024-Q3 | 90.0 |
| 2024-Q4 | 76.4 |
| 2025-Q1 | 86.2 |
| 2025-Q2 | 85.9 |
| 2025-Q3 | 86.0 |
| 2025-Q4 | 85.6 |
| 2026-Q1 | 61.9 |
| 2026-Q2 | 62.4 |
Active institutional exit or low consensus; avoid or liquidate
Trading +39.5% above funds' purchase price — elevated pullback risk
1 of 18 tracked funds hold CVS. Avg conviction: 0.1%. Net trimming. First tracked at $62.88 (current +39.5% vs tracked).
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Citadel Advisors | 0.1% | Reduce |